Quantcast

Latest Cathepsin Stories

2014-07-16 08:27:08

MENLO PARK, Calif., July 16, 2014 /PRNewswire/ -- Virobay, Inc., a clinical stage pharmaceutical company with a platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune disease and fibrosis, today announced the closing of an expanded Series B second tranche financing of $8.0 million. Including this recent $8 million investment, Virobay has raised an aggregate of $18 million in two tranches of the Series B financing. The first tranche...

2014-06-25 12:30:48

MENLO PARK, Calif., June 25, 2014 /PRNewswire/ -- Virobay, Inc., a clinical stage pharmaceutical company with a broad platform of cathepsin protease inhibitors being developed for the treatment of neuropathic pain, autoimmune diseases and fibrosis, today announced the appointment of James Welch as Chief Financial Officer, effective as of June 20, 2014. Mr. Welch has more than 20 years of experience in financial and operational management at life science and high technology firms....

2014-04-09 10:50:26

By incapacitating the activities of a protein that guides other proteins to fold into a stable shapes, Fox Chase Cancer Center researchers shut off the spigot for two proteases that help ovarian cancer cells chew their way out of the tissue they grow in and dig in at new locations. Building on earlier work that showed that inhibition of heat shock proteins—the protein origami helpers—limited metastases in ovarian cancer in mice, Shane W. O'Brien, MS, Scientific Assistant at Fox Chase...

2014-02-25 08:30:45

MENLO PARK, Calif., Feb. 25, 2014 /PRNewswire/ -- Virobay, Inc., a privately held biotechnology firm with a broad portfolio of cathepsin protease inhibitors for the treatment of neuropathic pain, autoimmune diseases, liver diseases and dermatological diseases, today announced that Thomas J. Dietz, Ph.D., has joined the board of Virobay as an independent director effective February 13, 2014. Dr. Dietz has more than 20 years of successful life-sciences industry experience. Prior to...

New Hope For Sleeping Sickness Drug
2012-11-30 12:32:48

Connie K. Ho for redOrbit.com — Your Universe Online Scientists from the Helmholtz Association of German Research Centers and the Department of Energy´s (DOE) SLAC National Accelerator Laboratory recently revealed that X-rays could provide information on a novel biological structure that could possibly be developed into a sleeping sickness drug. The findings were discovered with the help of a free-electron laser that is considered the most powerful in the world. Sleeping...

2012-03-29 23:27:19

A new study has identified a key mechanism that causes breast cancer to spread. The research, published by Cell Press on March 30th in the journal Molecular Cell, enhances our knowledge about the signals that drive cancer metastasis and identifies new therapeutic targets for a lethal form of invasive breast cancer that is notoriously resistant to treatment. Amplification of the gene for ErbB2 has been linked with aggressive forms of breast cancer and is associated with a poor outcome....


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related